Novavaxincis A Biotechnology Company Based In Gaithersburgmarylandspecializing In Vaccine Developmentfounded In 1987The Company Utilizes Recombinant Nanoparticle Technology And Its Proprietary Matrix Ma C Adjuvant To Create Vaccines For Infectious Diseaseswith Research And Manufacturing Facilities In The U S Swedenand The Czech Republicnovavax Employs Over 1 500 People As Of 2022 The Company Gained Prominence During The Covid 19 Pandemic With Its First Commercial Productnuvaxovida Protein Based Vaccine Authorized In Over 40 Countriesnovavax Is Also Developing Additional Covid 19 Vaccine Candidates And Has A Pipeline That Includes Vaccines For Ebolamerssarsand Influenzathe Company Aims To Address Global Health Challenges Through Vaccine Innovation And Seeks To Expand Its Technology To Benefit Billions Of Lives
No conferences found for this company.
| Company Name | Novavax Ab |
| Country |
Sweden
|
| Address | N/A |
| Telephone | N/A |
| N/A |
